Glossary of Clinical Trials Terms

There are a lot of terms used when talking about clinical trials and clinical research that might be unfamiliar. Please use the alphabetical guide to terms below to learn more about the components of clinical research.

An unintended reaction to a drug taken at normal doses.
Any untoward medical occurrence in a study subject administrated a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.
Doing no harm. Maximizing benefits while minimizing risks.
A virus, toxin, antitoxin, blood product, therapeutic serum or similar material for the prevention, treatment or cure of disease or injury in humans.
Any technique that uses living organisms or substances from living organisms, biological systems or processes to make or modify a product or process, to change plants or animals, or to develop microorganisms for specific uses.
The process through which study subjects, the investigator and/or other involved parties in a clinical trial are kept unaware of the treatment assignments of study subjects.
A record of pertinent information collected on each subject during a clinical trial, based on the protocol.
A clinical investigator who on a research study
Any experiment that involves a test article (drug, device, biologic) and one or more human subjects.
The sponsor monitor who visits sites periodically during a study to monitor the data and assess progress.
The person at an investigational site who manages the daily operations of a clinical investigation and who is responsible to the investigator.
A person or entity that assumes, as an independent contractor with the sponsor, one or more of the obligations of the sponsor.
A group of subjects who are not treated with the investigational product. This group is used as a comparison to the treatment group
The process of handling the data generated and collected during a clinical trial, usually including data entry and database management.
The characteristics of study subjects, including age, sex, medical history and other information relevant to the study.
An instrument, apparatus, implement, machine, contrivance, implant, in vitro (in a test tube, etc. rather than in the body) reagent or other similar or related article, including any component, part or accessory, which is intended for use in the diagnosis, cure, treatment or prevention of disease. A device does not achieve its intended purpose through chemical action in the body and is not dependent upon being metabolized to achieve its purpose.
The design of a study in which neither the investigator nor the subject knows which treatment the subject is receiving.
An article (other than food) intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals.
A test product’s ability to produce a beneficial effect on the duration or course of a disease.
The United States Food and Drug Administration.
The regulations and guidelines that specify the responsibilities of sponsors, investigators, monitors and IRBs involved in clinical trials. They are meant to protect the safety, rights and welfare of the subjects in addition to ensuring the accuracy of the data collected during the trial.
An individual who participates in research, either as a recipient of the test article or as a control. A subject may be either a healthy subject or a patient.
The characteristics that must be present (inclusion) or absent (exclusion) in order for a subject to qualify for a clinical trial, as per the protocol for the trial.
The process by which a subject voluntarily confirms his or her willingness to participate in a clinical trial.
Any board, committee, or group formally designated to review biomedical research involving humans as subjects, to approve the initiation of and conduct periodic review of such research.
An individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is dispensed, or, in the case of an investigation conducted by a team of individuals, is the responsible leader of that team.
A compilation of all information known to date about the test product, including chemistry and formulation information and preclinical and clinical data. It is updated at least annually. Once the product is marketed, it is replaced by the labeling (package insert) for the product.
A new drug or biologic that is used in a clinical investigation.
The application to start clinical testing of a new drug, biologic or device in humans.
Non-clinical testing conducted in an artificial environment such as a test tube or culture medium.
Testing conducted in living animal and human systems.
The determination of the IRB that the clinical investigation has been reviewed and may be conducted within the constraints set by the IRB and applicable regulations.
An individual or judicial or other body authorized under applicable law to consent on behalf of a potential subject to the subject’s participation in research.
The physician for the sponsor who is responsible for the clinical investigation of a test product.
The probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life or in the performance of routine physical or psychological examinations or tests.
The marketing application for a new drug submitted to the FDA. The NDA contains all the non-clinical, clinical, pharmacological, pharmacokinetic and stability data required by the FDA.
A study in which the subjects and the investigator are aware of the drug that is being administered.
An inactive substance designed to resemble the drug being tested.
Studies conducted on animals to determine that the drug is safe to use in studies on humans.
The formal plan for carrying out a clinical investigation.
Systems and procedures designed to ensure that a study is being preformed in accordance with Good Clinical Practice (GCP) guidelines and that the data being generated are accurate.
A method in which study subjects are randomly assigned to treatment groups. It helps to reduce bias in a trial by ensuring that there is no pattern in the way subjects are assigned to treatment groups.
Any untoward medical occurrence in a drug study that results in death, is life-threatening, requires hospitalization (or a prolongation of hospitalization in a patient who is already hospitalized), results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.
A group of investigational sites that have banded together and organized centrally to do studies.
The person or entity who initiates a clinical investigation, but who does not actually conduct the investigation.
Official written instructions for the management and conduct of clinical trial processes. SOPs ensure that research is carried out in a consistent and efficient manner.
The person at an investigational site who manages the daily operations of a clinical investigation and who is responsible to the investigator or study coordinator.
Any member of an investigational team other than the investigator or study coordinator.
Test Article
Any drug, biologic, or device being tested for use in humans.
Problem involving risks to human subjects participating in a clinical research study, e.g., breach of confidentiality, incorrect labeling of study drug. These need to be collected and reported.